Heart health monitoring for newly diagnosed AML patients
Part of Cancer, Heart & circulation clinical trials.
This study helps people with newly diagnosed acute myeloid leukemia (AML) by closely monitoring their heart health during chemotherapy. It aims to detect any early heart problems caused by treatment so they can be managed sooner.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 16 years or older and have been newly diagnosed with acute myeloid leukemia (AML).
- You are scheduled to receive either intensive chemotherapy (anthracycline-based) or a non-intensive regimen (venetoclax and/or hypomethylating agents).
- Your heart function must be at least 50% (checked by an echocardiogram) before starting the trial.
- You have not previously been treated with anthracycline chemotherapy or venetoclax/hypomethylating agents.
- You do not have severe structural heart disease, unstable irregular heartbeats, or poor heart imaging windows.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well your blood vessels and heart pumping ability work in people with acute myeloid leukemia (AML) receiving certain chemotherapy. It may help doctors better understand heart risk during treatment and tailor monitoring to you.
This Phase 2 study tests whether a blood-pressure medicine plan (a beta blocker plus lisinopril) can protect the heart in people newly diagnosed with acute myeloid leukemia (AML) who are starting anthracycline chemotherapy. It looks at heart safety by requiring a good heart scan before treatment and careful medication eligibility.
This study tests whether doing gentle exercise at home can help protect your heart during stem cell transplant treatment for acute myeloid leukemia (a type of blood cancer). You'll use a smartphone app to guide daily workouts designed to be safe and manageable during your treatment.
This study follows patients receiving a type of chemotherapy called anthracyclines to track how it affects the heart over time. The goal is to learn how to better protect heart health during cancer treatment.
This trial studies whether adding venetoclax to standard induction chemotherapy (homoharringtonine plus cytarabine) can improve outcomes for people with newly diagnosed AML. It mainly looks at people who can safely receive intensive chemotherapy but have certain heart, kidney, or lung limits.
This study compares different treatment intensities for adults with acute myeloid leukemia (AML) who are less able to handle strong chemotherapy. It aims to find the best approach for people with health issues like heart or lung problems that make standard chemo riskier.
Hear when a new Newly Diagnosed Acute Myeloid Leukemia (AML) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.